• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

支架免疫亲和素 FKBP51 是一种磷酸化蛋白,可进行动态的线粒体-核穿梭。

The Scaffold Immunophilin FKBP51 Is a Phosphoprotein That Undergoes Dynamic Mitochondrial-Nuclear Shuttling.

机构信息

Instituto de Biología y Medicina Experimental (IBYME)-CONICET, Buenos Aires 1428, Argentina.

Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires 1428, Argentina.

出版信息

Cells. 2022 Nov 25;11(23):3771. doi: 10.3390/cells11233771.

DOI:10.3390/cells11233771
PMID:36497030
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9739885/
Abstract

The immunophilin FKBP51 forms heterocomplexes with molecular chaperones, protein-kinases, protein-phosphatases, autophagy-related factors, and transcription factors. Like most scaffold proteins, FKBP51 can use a simple tethering mechanism to favor the efficiency of interactions with partner molecules, but it can also exert more complex allosteric controls over client factors, the immunophilin itself being a putative regulation target. One of the simplest strategies for regulating pathways and subcellular localization of proteins is phosphorylation. In this study, it is shown that scaffold immunophilin FKBP51 is resolved by resolutive electrophoresis in various phosphorylated isoforms. This was evidenced by their reactivity with specific anti-phosphoamino acid antibodies and their fade-out by treatment with alkaline phosphatase. Interestingly, stress situations such as exposure to oxidants or in vivo fasting favors FKBP51 translocation from mitochondria to the nucleus. While fasting involves phosphothreonine residues, oxidative stress involves tyrosine residues. Molecular modeling predicts the existence of potential targets located at the FK1 domain of the immunophilin. Thus, oxidative stress favors FKBP51 dephosphorylation and protein degradation by the proteasome, whereas FK506 binding protects the persistence of the post-translational modification in tyrosine, leading to FKBP51 stability under oxidative conditions. Therefore, FKBP51 is revealed as a phosphoprotein that undergoes differential phosphorylations according to the stimulus.

摘要

免疫亲和素 FKBP51 与分子伴侣、蛋白激酶、蛋白磷酸酶、自噬相关因子和转录因子形成异源复合物。像大多数支架蛋白一样,FKBP51 可以使用简单的连接机制来提高与伴侣分子相互作用的效率,但它也可以对客户因子施加更复杂的变构控制,免疫亲和素本身就是一个潜在的调节靶点。调节蛋白质途径和亚细胞定位的最简单策略之一是磷酸化。在这项研究中,表明支架免疫亲和素 FKBP51 可以通过分辨率电泳在各种磷酸化同工型中解析。这可以通过它们与特定的抗磷酸氨基酸抗体的反应性以及通过碱性磷酸酶处理而消失来证明。有趣的是,应激情况,如暴露于氧化剂或体内禁食,有利于 FKBP51 从线粒体易位到细胞核。虽然禁食涉及磷酸苏氨酸残基,但氧化应激涉及酪氨酸残基。分子建模预测了位于免疫亲和素 FK1 结构域的潜在靶标的存在。因此,氧化应激有利于 FKBP51 的去磷酸化和蛋白酶体降解,而 FK506 结合保护酪氨酸中翻译后修饰的持续存在,导致 FKBP51 在氧化条件下稳定。因此,FKBP51 被揭示为一种磷酸化蛋白,根据刺激条件发生不同的磷酸化。

相似文献

1
The Scaffold Immunophilin FKBP51 Is a Phosphoprotein That Undergoes Dynamic Mitochondrial-Nuclear Shuttling.支架免疫亲和素 FKBP51 是一种磷酸化蛋白,可进行动态的线粒体-核穿梭。
Cells. 2022 Nov 25;11(23):3771. doi: 10.3390/cells11233771.
2
The 90-kDa heat-shock protein (Hsp90)-binding immunophilin FKBP51 is a mitochondrial protein that translocates to the nucleus to protect cells against oxidative stress.90kDa 热休克蛋白(Hsp90)结合免疫亲和素 FKBP51 是一种线粒体蛋白,可转移到细胞核内以保护细胞免受氧化应激。
J Biol Chem. 2011 Aug 26;286(34):30152-60. doi: 10.1074/jbc.M111.256610. Epub 2011 Jul 5.
3
Hsp90-binding immunophilin FKBP51 forms complexes with hTERT enhancing telomerase activity.与热休克蛋白90结合的亲免蛋白FKBP51与端粒酶逆转录酶形成复合物,增强端粒酶活性。
Mol Oncol. 2016 Aug;10(7):1086-98. doi: 10.1016/j.molonc.2016.05.002. Epub 2016 May 17.
4
Dynamic mitochondrial-nuclear redistribution of the immunophilin FKBP51 is regulated by the PKA signaling pathway to control gene expression during adipocyte differentiation.在脂肪细胞分化过程中,免疫亲和素 FKBP51 通过 PKA 信号通路调节其在线粒体和核之间的动态再分布,从而控制基因表达。
J Cell Sci. 2013 Dec 1;126(Pt 23):5357-68. doi: 10.1242/jcs.125799. Epub 2013 Oct 7.
5
[The dynamic mitochondria-nuclear redistribution of FKBP51 during the process of adipocyte differentiation is regulated by PKA].[脂肪细胞分化过程中FKBP51的线粒体-细胞核动态重新分布受蛋白激酶A调控]
Medicina (B Aires). 2013;73(5):401-5.
6
Mitochondrial-nuclear communication by FKBP51 shuttling.通过FKBP51穿梭实现的线粒体-细胞核通讯
J Cell Biochem. 2024 Dec;125(12):e30386. doi: 10.1002/jcb.30386. Epub 2023 Feb 23.
7
NF-κB transcriptional activity is modulated by FK506-binding proteins FKBP51 and FKBP52: a role for peptidyl-prolyl isomerase activity.核因子κB转录活性受FK506结合蛋白FKBP51和FKBP52调节:肽基脯氨酰异构酶活性的作用。
J Biol Chem. 2014 Sep 19;289(38):26263-26276. doi: 10.1074/jbc.M114.582882. Epub 2014 Aug 7.
8
Mitochondria-nucleus shuttling FK506-binding protein 51 interacts with TRAF proteins and facilitates the RIG-I-like receptor-mediated expression of type I IFN.线粒体-细胞核穿梭蛋白FK506结合蛋白51与肿瘤坏死因子受体相关因子(TRAF)蛋白相互作用,并促进维甲酸诱导基因I样受体介导的I型干扰素表达。
PLoS One. 2014 May 1;9(5):e95992. doi: 10.1371/journal.pone.0095992. eCollection 2014.
9
FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells.FK506结合蛋白51和52对哺乳动物细胞中动力蛋白与糖皮质激素受体的相互作用及核转位具有不同的调节作用。
J Biol Chem. 2005 Feb 11;280(6):4609-16. doi: 10.1074/jbc.M407498200. Epub 2004 Dec 9.
10
Calcium- and FK506-independent interaction between the immunophilin FKBP51 and calcineurin.亲免素FKBP51与钙调神经磷酸酶之间不依赖钙和FK506的相互作用。
J Cell Biochem. 2002;84(3):460-71. doi: 10.1002/jcb.10026.

引用本文的文献

1
The inhibition of FKBP5 protects β-cell survival under inflammation stress via AKT/FOXO1 signaling.FKBP5 的抑制通过 AKT/FOXO1 信号通路在炎症应激下保护 β 细胞存活。
Cell Death Discov. 2023 Jul 14;9(1):247. doi: 10.1038/s41420-023-01506-x.
2
FKBP51 plays an essential role in Akt ubiquitination that requires Hsp90 and PHLPP.FKBP51 在 Akt 泛素化中发挥重要作用,该过程需要 HSP90 和 PHLPP。
Cell Death Dis. 2023 Feb 13;14(2):116. doi: 10.1038/s41419-023-05629-y.

本文引用的文献

1
Glucocorticoid Receptor Signaling in Diabetes.糖皮质激素受体信号在糖尿病中的作用。
Int J Mol Sci. 2021 Oct 16;22(20):11173. doi: 10.3390/ijms222011173.
2
PD-L1 Expression Fluctuates Concurrently with Cyclin D in Glioblastoma Cells.胶质母细胞瘤细胞中 PD-L1 表达与细胞周期蛋白 D 同步波动。
Cells. 2021 Sep 9;10(9):2366. doi: 10.3390/cells10092366.
3
Corticosteroid receptors as a model for the Hsp90•immunophilin-based transport machinery.皮质甾类受体作为热休克蛋白 90•免疫亲和素基转运机制的模型。
Trends Endocrinol Metab. 2021 Oct;32(10):827-838. doi: 10.1016/j.tem.2021.07.005. Epub 2021 Aug 20.
4
The Hsp90-binding immunophilin FKBP52 enhances neurodifferentiation and neuroregeneration in murine models.与热休克蛋白90(Hsp90)结合的亲免素FKBP52可增强小鼠模型中的神经分化和神经再生。
Neural Regen Res. 2022 Mar;17(3):555-556. doi: 10.4103/1673-5374.320976.
5
AmotL2, IQGAP1, and FKBP51 Scaffold Proteins in Glioblastoma Stem Cell Niches.胶质母细胞瘤干细胞龛中的 AmotL2、IQGAP1 和 FKBP51 支架蛋白。
J Histochem Cytochem. 2022 Jan;70(1):9-16. doi: 10.1369/00221554211025480. Epub 2021 Jun 24.
6
The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51.非受体酪氨酸激酶SRMS通过磷酸化支架蛋白FKBP51来抑制自噬并促进肿瘤生长。
PLoS Biol. 2021 Jun 2;19(6):e3001281. doi: 10.1371/journal.pbio.3001281. eCollection 2021 Jun.
7
Differential regulation of the glucocorticoid receptor nucleocytoplasmic shuttling by TPR-domain proteins.TPR 结构域蛋白对糖皮质激素受体核质穿梭的差异调节。
Biochim Biophys Acta Mol Cell Res. 2021 May;1868(6):119000. doi: 10.1016/j.bbamcr.2021.119000. Epub 2021 Mar 4.
8
Reactive Oxygen Species: Drivers of Physiological and Pathological Processes.活性氧:生理和病理过程的驱动因素
J Inflamm Res. 2020 Dec 2;13:1057-1073. doi: 10.2147/JIR.S275595. eCollection 2020.
9
Proof that the high molecular weight immunophilin FKBP52 mediates the in vivo neuroregenerative effect of the macrolide FK506.证明高分子量免疫亲和素 FKBP52 介导了大环内酯类 FK506 的体内神经再生作用。
Biochem Pharmacol. 2020 Dec;182:114204. doi: 10.1016/j.bcp.2020.114204. Epub 2020 Aug 20.
10
FK506 binding proteins and inflammation related signalling pathways; basic biology, current status and future prospects for pharmacological intervention.FK506结合蛋白与炎症相关信号通路;基础生物学、现状及药物干预的未来前景
Pharmacol Ther. 2020 Nov;215:107623. doi: 10.1016/j.pharmthera.2020.107623. Epub 2020 Jul 2.